Week In Review: Suzhou's Adagen Raises $140 Million In U.S. IPO To Develop Oncology DrugsSeeking Alpha • 02/14/21
Adagene Inc. Announces Closing of Initial Public Offering and Exercise of Underwriters' Over-Allotment OptionGlobeNewsWire • 02/11/21